Elicio Therapeutics ELTX
NASDAQ ELTX
$1.63 +0.02 (+1.24%)
At close: Nov 11, 2026 · 4:00 PM EST

Elicio Therapeutics (ELTX) Non-Current Deferred Revenue (2020 - 2021)

Updated

Elicio Therapeutics' Non-Current Deffered Revenue was $23.77 million in Q3 2021, up 0.3% from the prior quarter.

Analysis

Elicio Therapeutics (ELTX) Non-Current Deferred Revenue (2020 - 2021) Analysis & Trends

At the end of FY2020, Non-Current Deffered Revenue at Elicio Therapeutics came in at $25.87 million.

  • Quarterly Non-Current Deffered Revenue has moved between $23.71 million (Q2 2021) and $25.87 million (Q4 2020) over five years.
  • Per Business Quant data, ELTX's Non-Current Deffered Revenue in the three quarters before Q3 2021 was $23.71 million (Q2 2021), $25.64 million (Q1 2021) and $25.87 million (Q4 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Elicio Therapeutics 45.57 Mn -42.34 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 23.77 Mn
Jun 30, 2021 23.71 Mn
Mar 31, 2021 25.64 Mn
Dec 31, 2020 25.87 Mn
API Access

Elicio Therapeutics Non-Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=ELTX&period=max&api_key=YOUR_API_KEY